Edison Group recently interviewed our Chairman, Kevin Crofton. In this interview he discusses the rationale for the stake sale and medium-term strategic focus on growing the core electrosurgical franchise, as well as fostering partnerships for its Kamaptive Technology and CROMA platform. Read more about this interview below. A full video interview is also available to watch on the Edison Group website.

Interview by Jyoti Prakash - Healthcare Director at Edison Group:

UK-based Creo Medical focuses on the development and commercialisation of minimally invasive electrosurgical devices. Its six products in the flagship CROMA platform have all been CE marked, with five cleared by the FDA. The company recently concluded the sale of a 51% stake in its European consumables business for net proceeds of €30m, valuing the business at €72m.

In this interview, we speak to Kevin Crofton, the chairman of Creo Medical and a notable name in the semiconductors space, about what has been a strategically important period for the company. Kevin discusses the rationale for the stake sale and medium-term strategic focus on growing the core electrosurgical franchise, as well as fostering partnerships for its Kamaptive technology and CROMA platform. He also mentions the recent cost savings implemented by the company and how, alongside recent developments, this puts Creo in a strong position to achieve break-even.

With several catalysts on the horizon in the next 12–18 months, including new product launches and the advancement of its collaboration with robotics leader Intuitive Surgical, 2025 is gearing up to be an active year for Creo.